Skip to content

Garrison Speaks on Global Access to Medicines and Pricing in China

Professor Emeritus Lou Garrison recently visited China to give four talks on pharmaceutical market design and global differential pricing. He gave the keynote address for a new book launch at China Europe International Business School in Shanghai for Professors Eric Bouteiller and Annie Chicoye for their new book “Fundamentals of Market Access for Pharmaceuticals.” Lou commented that: “Our field has done a poor job of communicating the economics of pharmaceutical market design in terms of the role of the patent system in promoting innovation and improving access through generics. I highly recommend this book for not only providing the economic fundamentals but also explaining the complexities and challenges in improving real-world access for patients.”

From left: Eric Bouteiller, Hiroshi Nakamura, Jung Wonjoo, Shanlian Hu, Lou, François Houÿez, Vivian Chen, Joseph Saba, Annie Chicoye
From left: Eric Bouteiller, Hiroshi Nakamura, Jung Wonjoo, Shanlian Hu, Lou, François Houÿez, Vivian Chen, Joseph Saba, Annie Chicoye

Link to book introduction:  https://www.youtube.com/watch?v=U-WHaqhbB1I

Lou was also graciously hosted and gave talks at Roche China, China Pharmaceutical University (in Nanking) and Fudan University.

Lou was honored to speak to students at Fudan University and with pharmacoeconomic faculty and Chinese thought leaders (from left) Professors Wen Chen, Shanlian Hu, and Min Hu.
Lou was honored to speak to students at Fudan University and with pharmacoeconomic faculty and Chinese thought leaders (from left) Professors Wen Chen, Shanlian Hu, and Min Hu.

His talk emphasized the need to promote better global differential pricing to improve global assess to innovative medicines through more rapid and efficient health technology.  He said: “China is a great example of how to accelerate access, having made great progress since I first lectured about Markov modeling to the Central Drug Committee fifteen years ago.”

Lou also mentioned the ongoing work of ISPOR Global Access to Medical Innovation Special Interest Group that he helps to lead and his aim to accelerate its work in 2025.